Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study

Abstract

Aims: We aimed to observe the improvements in cardiac function indexes and the occurrence of adverse events in patients with heart failure with reduced ejection fraction (HFrEF) after dapagliflozin administration in a real-world setting.Methods: We retrospectively enrolled 201 patients with HFrEF who were treated at a tertiary hospital in Zhengzhou and started to take dapagliflozin (10 mg/d) from March 2020 to June 2021. Their New York Heart Association (NYHA) functional class, cardiac ultrasound indexes, laboratory indexes, and vital signs between baseline and the last follow-up visit were compared, and their adverse events during the follow-up period were recorded.Results: The follow-up period was 173 (67–210) days. The cardiac function indexes of patients at follow-up, compared with baseline, indicated significant improvement (proportion of NYHA functional class I and II: 40.8% vs. 56.2%; left ventricular ejection fraction: 28.4 ± 5.3% vs. 34.7 ± 5.9%; left ventricular end-diastolic diameter: 70.1 ± 6.4 mm vs. 64.7 ± 5.6 mm; N-terminal pro-B-type natriuretic peptide: 5421.9 ± 2864.4 pg/mL vs. 2842.8 ± 1703.4 pg/mL at baseline vs. at follow-up; all P < 0.05). The rates of hypotension, deterioration of renal function, and genital infection during the follow-up period were 6.5%, 4.0%, and 3.5%, respectively.Conclusions: We believe that dapagliflozin is safe and effective in patients with HFrEF in the real world.